Transaction · 0001193125-26-382245

Bizily Scott

Bizily Scott, CLO, reported an open-market or private sale at 4D Molecular Therapeutics, Inc. involving 584.000000 shares for an estimated $8176.00. Reported holdings after the transaction were 8617.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCLO
FDMT4D Molecular Therapeutics, Inc.
Filing timeSep 03
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$14.70
Pre-filing
1mo ago -30.7%1w ago +6.3%1d ago -4.0%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

FDMT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
FDMT since 2026-09-03Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-382245
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 10:55 PM · 2d delay
Shares
584 sh
$1.40k per share
Estimated value
-$817k
Computed from shares × price
Holdings after
8.61k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

  2. F2

    The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such…

Original filing · 0001193125-26-382245
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

FDMT